.Attributes Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ sophisticated breast cancer cells and active or even steady brain metastases showed constant intracranial task and wide spread effectiveness of T-DXd.